Last reviewed · How we verify

Allergy and Asthma Center of El Paso — Portfolio Competitive Intelligence Brief

Allergy and Asthma Center of El Paso pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Advair HFA MDI 115/21 Advair HFA MDI 115/21 marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory/Pulmonology
Symbicort 160/4.5 pMDI Symbicort 160/4.5 pMDI marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol) Respiratory/Pulmonology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. SkyePharma AG · 2 shared drug classes
  2. AstraZeneca · 2 shared drug classes
  3. GlaxoSmithKline · 2 shared drug classes
  4. Chiesi Farmaceutici S.p.A. · 2 shared drug classes
  5. EMS · 1 shared drug class
  6. Far Eastern Memorial Hospital · 1 shared drug class
  7. Allergy & Asthma Medical Group & Research Center · 1 shared drug class
  8. Gelb, Arthur F., M.D. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Allergy and Asthma Center of El Paso:

Cite this brief

Drug Landscape (2026). Allergy and Asthma Center of El Paso — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/allergy-and-asthma-center-of-el-paso. Accessed 2026-05-17.

Related